Lattime Laboratory - Select Publications

View Dr. Lattime’s Complete List of Published Work in MyBibliography.


White E, Lattime EC, Guo JY. Autophagy Regulates Stress Responses, Metabolism, and Anticancer Immunity. Trends Cancer. 2021;7(8):778-89. Epub 20210607. doi: 10.1016/j.trecan.2021.05.003. PubMed PMID: 34112622; PMCID: PMC8295230.

Yuan Z, Gardiner JC, Maggi EC, Huang S, Adem A, Bagdasarov S, Li G, Lee S, Slegowski D, Exarchakis A, Howe JR, Lattime EC, Zang X, Libutti SK. B7 immune-checkpoints as targets for the treatment of neuroendocrine tumors. Endocr Relat Cancer. 2021;28(2):135-49. Epub 2021/01/08. doi: 10.1530/ERC-20-0337. PubMed PMID: 33410766; PMCID: PMC8486311.

Poillet-Perez L, Sharp DW, Yang Y, Laddha SV, Ibrahim M, Bommareddy PK, Hu ZS, Vieth J, Haas M, Bosenberg MW, Rabinowitz JD, Cao J, Guan JL, Ganesan S, Chan CS, Mehnert JM, Lattime EC, White E. Autophagy promotes growth of tumors with high mutational burden by inhibiting a T-cell immune response. Nat Cancer. 2020;1(9):923-34. Epub 20200918. doi: 10.1038/s43018-020-00110-7. PubMed PMID: 34476408; PMCID: PMC8409526.

Portal DE, Weiss RE, Wojtowicz M, Mansour A, Monken C, Mehnert JM, Aisner JA, Kane M, Nishioka J, Aisner S, Peters S, Stein MN, Kim IY, Mayer TM, Shih W, Gulley J, Streicher H, Singer EA, Lattime EC. Phase I neoadjuvant study of intravesical recombinant fowlpox-GM-CSF (rF-GM-CSF) or fowlpox-TRICOM (rF-TRICOM) in patients with bladder carcinoma. Cancer Gene Ther. 2020;27(6):438-47. Epub 20190620. doi: 10.1038/s41417-019-0112-z. PubMed PMID: 31222182; PMCID: PMC6923616.

Poillet-Perez L, Xie X, Zhan L, Yang Y, Sharp DW, Hu ZS, Su X, Maganti A, Jiang C, Lu W, Zheng H, Bosenberg MW, Mehnert JM, Guo JY, Lattime E, Rabinowitz JD, White E. Autophagy maintains tumour growth through circulating arginine. Nature. 2018;563(7732):569-73. Epub 20181114. doi: 10.1038/s41586-018-0697-7. PubMed PMID: 30429607; PMCID: PMC6287937.

Panda A, Betigeri A, Subramanian K, Ross JS, Pavlick DC, Ali S, Markowski P, Silk A, Kaufman HL, Lattime E, Mehnert JM, Sullivan R, Lovly CM, Sosman J, Johnson DB, Bhanot G, Ganesan S. Identifying a clinically applicable mutational burden threshold as a potential biomarker of response to immune checkpoint therapy in solid tumors. JCO Precis Oncol. 2017;2017. Epub 20171207. doi: 10.1200/PO.17.00146. PubMed PMID: 29951597; PMCID: PMC6016848.

Kohlhapp FJ, Huelsmann EJ, Lacek AT, Schenkel JM, Lusciks J, Broucek JR, Goldufsky JW, Hughes T, Zayas JP, Dolubizno H, Sowell RT, Kühner R, Burd S, Kubasiak JC, Nabatiyan A, Marshall S, Bommareddy PK, Li S, Newman JH, Monken CE, Shafikhani SH, Marzo AL, Guevara-Patino JA, Lasfar A, Thomas PG, Lattime EC, Kaufman HL, Zloza A. Non-oncogenic acute viral infections disrupt anti-cancer responses and lead to accelerated cancer-specific host death. Cell Rep. 2016;17(4):957-65. Epub 2016/10/21. doi: 10.1016/j.celrep.2016.09.068. PubMed PMID: 27760326, PMCID: PMC5589518.

Sharp, DW, Lattime EC. Recombinant poxvirus and the tumor microenvironment: oncolysis, immune regulation and immunization. Biomedicines. 2016;4(3):19. Epub 20160812. doi: 10.3390/biomedicines4030019. PubMed PMID: 28191451, PMCID: PMC5298125.

Cui R, Yue W, Lattime EC, Stein MN, Xu Q, Tan XL. Targeting tumor-associated macrophages to combat pancreatic cancer. Oncotarget. 2016;7(31):50735-54. Epub 2016/05/19. doi: 10.18632/oncotarget.9383. PubMed PMID: 27191744, PMCID: PMC5226617.

DiPaola RS, Chen YH, Bubley GJ, Stein MN, Hahn NM, Carducci MA, Lattime EC, Gulley JL, Arlen PM, Butterfield LH, Wilding G. A national multicenter phase 2 study of prostate-specific antigen (PSA) pox virus vaccine with sequential androgen ablation therapy in patients with PSA progression: ECOG 9802. Eur Urol. 2015;68(3):365-71. Epub 20141218. doi: 10.1016/j.eururo.2014.12.010. PubMed PMID: 25533418, PMCID: PMC4472612.

de Vries CR, Monken CE, Lattime EC. The addition of recombinant vaccinia HER2/neu to oncolytic vaccinia-GMCSF given into the tumor microenvironment overcomes MDSC-mediated immune escape and systemic anergy. Cancer Gene Ther. 2015;22(3):154-62. Epub 20150130. doi: 10.1038/cgt.2015.2. PubMed PMID: 25633483, PMCID: PMC4397129.

de Vries CR, Kaufman HL, Lattime EC. Oncolytic viruses: Focusing on the tumor microenvironment. Cancer Gene Ther. 2015;22(4):169-71. Epub 20150227. doi: 10.1038/cgt.2015.11. PubMed PMID: 25721204.

de Vries CR, Poplin E, Weiss RE, August DA, Gabriel E, DiPaola RS, Lattime EC. Poxvirus-based strategies for combined vaccine and tumor microenvironment manipulation In: Gene Therapy of Cancer: Translational Approaches from Preclinical Studies to Clinical Implementation. Third ed. Lattime EC, Gerson SL, editors. San Diego: Academic Press; 2014. p. 241-257.

Gene Therapy of Cancer: Translational Approaches from Preclinical Studies to Clinical Implementation. Third ed. Lattime EC, Gerson SL, editors. San Diego: Academic Press; 2014. 537 p.

Nikitczuk KP, Schloss RS, Yarmush ML, Lattime EC. PLGA-polymer encapsulating tumor antigen and CpG DNA administered into the tumor microenvironment elicits a systemic antigen-specific IFN-γ response and enhances survival J Cancer Ther. 2013;4(1):280-90. Epub 2013/06/07. doi: 10.4236/jct.2013.41035. PubMed PMID: 23741626, PMCID: PMC3670804.

Moloughney JG, Monken CE, Tao H, Zhang H, Thomas JD, Lattime EC, Jin S. Vaccinia virus leads to ATG12-ATG3 conjugation and deficiency in autophagosome formation. Autophagy. 2011;7(12):1434-47. Epub 2011/10/26. doi: 10.4161/auto.7.12.17793. PubMed PMID: 22024753, PMCID: PMC3327614.

Nikitczuk KP, Lattime EC, Schloss RS, Yarmush ML. Analysis of dendritic cell stimulation utilizing a multi-faceted nanopolymer delivery system and the immune modulator 1-methyl tryptophan. Nano Life. 2010;1(3-4):239-50. Epub 2010/09/01. doi: 10.1142/S1793984410000171. PubMed PMID: 24772192, PMCID: PMC3998209.

DiPaola RS, Lattime EC. Bacillus Calmette-Guerin mechanism of action: the role of immunity, apoptosis, necrosis and autophagy. J Urol. 2007;178(5):1840-1. Epub 20070917. doi: 10.1016/j.juro.2007.08.063. PubMed PMID: 17868741.

Gabriel EM, Lattime EC. Anti-CTL-associated antigen 4: are regulatory T cells a target? Clin Cancer Res. 2007;13(3):785-8. Epub 2007/02/10. doi: 10.1158/1078-0432.CCR-06-2820. PubMed PMID: 17289867.